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ABSTRACT
Radium-223 dichloride (Ra-223) is the first bone-targeting agent showing 
improvement in overall survival in patients with castration-resistant prostate cancer 
(CRPC) and bone metastases. We aimed to assess feasibility of Ra-223 treatment in 
patients with metastatic hormone-sensitive prostate cancer (mHSPC). Ten patients 
with primary bone metastases received Ra-223 following radical prostatectomy 
(RP). Changes in alkaline phosphatase (ALP) and prostate-specific antigen (PSA) 
were recorded, while pain intensity was evaluated using the self-reporting Brief Pain 
Inventory (BPI) questionnaire. Bone scintigraphy (BS) was performed to assess 
treatment response. Seven patients completed six cycles of Ra-223. Discontinuation 
was due to leuko- and lymphopenia, progressive lymph node metastasis or newly 
diagnosed liver metastasis. Treatment-related adverse events occurred in three 
patients and included leuko- and lymphopenia, fatigue, abdominal discomfort and 
nausea. Overall, a median decrease of 28% in ALP and a median decrease of 83% in 
PSA were noted at follow-up. However, PSA progressed in five patients at follow-up. 
Improvement of pain was observed in all patients (median decrease of 36% after 3 
cycles and of 40% at the end of therapy). On BS, three patients showed remission, 
four had stable disease, and one showed progressive disease at follow-up. Our results 
suggest that Ra-223 for primary bone metastases in patients with mHSPC after RP is 
feasible and alleviates pain. ALP, rather than PSA, may be a good marker for assessing 
treatment response. Ra-223 could therefore be taken into consideration as part of a 
multimodal approach for carefully selected patients with advanced prostate cancer.
INTRODUCTION
In patients with metastatic castration-resistant 
prostate cancer (mCRPC), bone is a common metastatic 
site, with 33% of patients developing bone metastases at 
two years [1]. Overall, up to 90% of patients with mCRPC 
will show radiological evidence of bone metastases [2], 
which may lead to skeletal-related events (SREs) [3]. 
SREs are significantly affecting the patient’s mobility, 
functional status and quality of life (QOL) [4], and may 
initially reduce survival in these patients [5]. Without any 
treatment, approximately 50% of patients with mCRPC 
and bone metastases will experience at least one SRE 
during a 24-month follow-up period [6].
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 27), pp: 44131-44140
Research Paper
Oncotarget44132www.impactjournals.com/oncotarget
Radium-223 dichloride (Ra-223) is a targeted 
alpha-emitter which acts as a calcium mimetic by forming 
complexes with the bone mineral hydroxyapatite [7]. 
It selectively accumulates in areas of bone with high 
turnover (eg, bone metastases) and emits heavy alpha-
particles that have a short penetration range with less than 
100 μm [7, 8]. To date, Ra-223 is the first bone-targeting 
agent to demonstrate improved overall survival in patients 
with CRPC and bone metastases, in addition to palliating 
bone pain, improvement in QOL, and prolonging time to 
SREs at the same time [9].
While the combination of chemotherapy and 
hormone therapy has shown to significantly improve 
survival in metastatic hormone-sensitive prostate cancer 
(mHSPC) patients in recent randomized trials [10, 11], not 
all patients qualify or are willing to undergo chemotherapy. 
Cytoreductive surgery for mHSPC patients is an emerging 
area of interest [12, 13]. Potential benefits include local 
control, delayed initiation of androgen deprivation therapy 
(ADT), and possibly improved oncologic outcome [14]. 
Currently, multiple trials are ongoing to assess the benefits 
of radical prostatectomy (RP) in mHSPC patients with 
bone metastases as part of multimodal treatment.
In this present study, we aimed to evaluate the 
feasibility of off-label Ra-223 treatment in mHSPC 
patients with primary bone metastases after RP.
RESULTS
Patient characteristics and Ra-223 treatment
Patient characteristics and Ra-223 treatment are 
summarized in Table 1  and 2, respectively. Mean patient 
age was 67 ± 12.4 years. All patients were diagnosed 
with extraprostatic, high-grade disease at RP specimen 
and had radiological or scintigraphic evidence of bone 
metastases (cM1b) at presentation (Table 1). On average, 
Ra-223 treatment was started 22.2 ± 32.0 months after 
initial diagnosis of prostate cancer (PCa) and 7.9 ± 9.9 
months after RP. Seven patients completed all six cycles 
of Ra-223 (mean cumulative dose 24.6 ± 4.9 MBq). 
Treatment-related adverse events were observed in three 
patients (patients 3, 4 and 7). Fatigue was reported in 
two patients (patients 4 and 7). Patient 7 additionally 
reported mild abdominal discomfort and nausea. 
Fatigue, abdominal discomfort and nausea did not affect 
continuation of therapy. Overall changes in blood counts 
are presented in Table 3. We found slight to moderate 
decreases - which did not affect continuation of Ra-223 
treatment (except in patient 3) - in erythrocytes and 
lymphocytes in all patients, in hemoglobin, leukocytes 
and neutrophils in nine patients, and in thrombocytes in 
eight patients. In patient 3, neutrophils decreased from 
2.46 G/l to 1.52 G/l (Common Terminology Criteria for 
Adverse Events (CTCAE) Grade I) and lymphocytes 
decreased from 1.3 G/l to 0.55 G/l (CTCAE Grade 
II) leading to discontinuation of treatment after cycle 
3. In the two other patients, Ra-223 treatment was 
discontinued due to newly diagnosed liver metastasis 
(patient 9), or to progressive pelvic lymphadenopathy 
after cycle 2, resulting in lymphedema of the lower 
extremities and radiotherapy was initiated (patient 10).
Changes in ALP and PSA
Baseline alkaline phosphatase (ALP) level varied 
from 52 to 360 U/l (mean ALP 123.3 ± 101.2 U/l) prior 
to first Ra-223 administration. Individual changes in ALP 
values are shown in Figure 1a. Mean and median ALP 
decreased by 22 ± 29% and by 28% at follow-up compared 
to baseline. At follow-up or after discontinuation of Ra-
223 treatment, partial response (decrease in ALP between 
25-75%) was seen in four patients (patients 5-8) and 
stable disease (ALP change from -25% to +25%) in six 
patients (patients 1-4 and 9-10). Complete response in 
ALP (decrease in ALP >75%) and progression (increase 
in ALP >25%) were not observed. Overall, nine patients 
had a decrease in ALP at follow-up. One patient (patient 
1) with progressive disease on bone scintigraphy (BS) 
presented with an ALP increase of 23%. Decrease in 
ALP was more evident in patients with partial remission 
(mean decrease 36 ± 30%) compared with patients with 
stable disease on BS (mean decrease 21 ± 13%). Baseline 
prostate-specific antigen (PSA) values varied from 0.11 to 
529 ng/mL (mean PSA 75.5 ± 172.5 ng/mL). Individual 
changes in PSA values are shown in Figure 1b. Mean PSA 
increased by 523 ± 981% (median PSA decreased by 83%) 
at follow-up compared to baseline. At follow-up or after 
discontinuation of Ra-223 treatment, good response in 
PSA (decrease in PSA >75%) was seen in five patients 
(patients 2, 3 and 6-8), and PSA progression (increase in 
PSA >25%) in five patients (patients 1, 4, 5, 9, 10).
Pain scores
Improvement of bone pain was observed in all 
patients. Mean pain intensity assessed by self-reporting 
Brief Pain Inventory (BPI) questionnaire [15], decreased 
by 43 ± 44% after 3 cycles of Ra-223 and by 45 ± 41% 
at the end of treatment compared to baseline (Figure 1c).
Bone metastases
Three patients responded well to Ra-223 treatment 
with a decrease in extent of the disease (EOD) score (partial 
remission; patients 4, 5, and 8). In two of these patients 
(patients 4 and 5) ≥1 bone lesion was not visible anymore 
on BS during follow-up visit (Figures 2a-2c, 3a-3c). In four 
patients stable disease was documented after six cycles of 
Ra-223 (patients 2, 6 and 7), or after three cycles of Ra-223 
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(patient 3), respectively. Furthermore, progress of disease 
with an increase in EOD score was noticed in patient 1. In 
two patients (patients 9 and 10) BS was not performed due 
to early discontinuation of Ra-223 treatment.
DISCUSSION
In patients with newly diagnosed mHSPC 
chemohormonal therapy leads to significantly improved 
survival [10, 11]. However, not all patients qualify for 
chemotherapy. Cytoreductive surgery may represent 
an additional option. Recent trials showed that RP can 
be performed safely in selected patients with mHSPC 
[13]; in addition, recent series showed significant 
survival benefits in patients with mHSPC after RP 
[12, 16]. However, these studies are limited by their 
retrospective nature and potential selection bias. 
Randomized controlled trials are needed and currently 
ongoing in Europe and the US (e.g. NCT02454543, 
NCT01751438).
In a patient with systemic disease it is evident 
that RP can only be one step in a multimodal approach. 
Complications of co-existing bone metastases in both 
castration-resistant and hormone-sensitive PCa patients, 
such as pain or SREs, may have significant impact on their 
daily life [4]. The alpha-emitter Ra-223 is the first agent 
delaying the onset of these complications and to improve 
quality of life and to prolong overall survival [9]. Yet, Ra-
223 has only been approved in patients with mCRPC. To 
date, there are no data available with regard to Ra-223 
treatment for primary bone metastases in patients with 
mHSPC after RP. Thus, the aim of our study was to test 
the feasibility of Ra-223 treatment in this specific patient 
cohort.
Treatment-related adverse events in our study 
were manageable and similar to those recorded in the 
ALSYMPCA trial [9]. Fatigue was the most common 
adverse event in our patient cohort (2 of 10 patients), 
which was reported in 26% of patients in the Ra-
223 group by Parker et al. [9, 17]. In our study, three 
patients did not complete all six cycles of Ra-233. 
Discontinuation was due to leuko- and lymphopenia, 
newly diagnosed liver metastasis, or progressive lymph 
node metastasis. In patient 3, neutrophils were low, but 
still in normal range prior to first Ra-223-treatment. 
After initiation of Ra-223 a significant decrease in 
neutrophils was observed prompting us to discontinue 
treatment in this patient. The newly diagnosed liver 
metastasis in patient 10 during Ra-223 treatment 
indicated the aggressiveness of his disease, leading to 
his early death approximately nine months after RP. 
Patient 10 showed progressive pelvic lymphadenopathy 
on computed tomography (CT), resulting in lymphedema 
of the lower extremities. As a result, treatment was 
interrupted after cycle 2 and radiotherapy was initiated. 
In this patient, only four lymph nodes were removed 
during RP, which was due to massive adhesions caused 
by former bilateral open hernia repairs with surgical 
mesh implantation. More extensive pelvic lymph node 
dissection (pLND) might have prevented progressive 
lymph node metastasis in this patient and thus, Ra-223 
treatment might have not been discontinued.
Complete response in PSA was seen in five patients; 
the other 50% of patients showed an increasing PSA at 
follow-up when compared to baseline PSA. Increases 
in PSA levels might be explained by new occurrence 
or progression of lymph node metastasis or visceral 
metastasis at the time of therapy. In our study, CT or 
positron emission tomography (PET)/CT scan to evaluate 
extraosseous metastases were not performed on a regular 
basis. On the other hand, in some patients ADT was started 
shortly before the first Ra-223 administration and thus, 
decrease in PSA is partly due to this effect. In a previous 
study, PSA levels did not correlate well with findings on 
BS [18]. Therefore, PSA might not be the ideal marker 
for evaluating response to Ra-223 treatment. ALP instead 
might be a better marker for evaluating response to Ra-223 
treatment. An increase in ALP was only seen in one patient 
(patient 1). This increase correlated with the patient’s 
progressive disease on BS.
Table 1: Patient characteristics
Patient 1 2 3 4 5 6 7 8 9 10
Age (yr) 79 55 77 76 67 53 60 71 46 82
Date of RP Mar 2014 Mar 2014 Mar 2015 Feb 2014 Jun 2013 Oct 2013 Sep 2012 Aug 2013 Oct 2013 Nov 2014
Histopathology pT3b pN1 
(1/24) cM1b 
R1
pT3b pN1 
(4/8) cM1b 
R0
pT3b pN0 
(0/27) cM1b 
R1
pT3b pN1 
(6/6) cM1b 
R1
pT3b pN1 
(1/9) cM1b 
R1
pT3b pN1 
(4/18) cM1b 
R1
pT3a pN0 
(0/21) cM1b 
R0
pT3b pN1 
(2/11) cM1b 
R1
pT3b pN1 
(5/29) 
cM1b R1
pT3b pN1 
(1/4) cM1b 
R1
Gleason score 9 (5+4) 8 (5+3) 9 (4+5) 9 (4+5) 10 (5+5) 9 (4+5) 9 (4+5) 9 (5+4) 10 (5+5) 9 (5+4)
PSA at 
diagnosis 
(ng/mL)
4.6 186 694 117 43.5 289 17 7278 18.4 23
RP = Radical prostatectomy; PSA = Prostate-specific antigen.
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Table 3: Change in blood counts during Ra-223 treatment
change
Hemoglobin Erythrocytes Leukocytes Thrombocytes Neutrophils Lymphocytes
absolute 
change
(g/dL)
relative
change
(%)
absolute 
change
(T/L)
relative 
change
(%)
absolute 
change
(g/L)
relative 
change
(%)
absolute 
change
(g/L)
relative 
change
(%)
absolute 
change
(g/L)
relative 
change
(%)
absolute 
change
(g/L)
relative 
change
(%)
Mean -0.90 -6.95 -0.43 -10.26 -1.08 -19.75 -22.20 -9.41 -0.54 -15.50 -0.37 -27.77
Median -0.85 -6.58 -0.51 -12.03 -1.17 -18.60 -11.00 -4.68 -0.68 -19.45 -0.37 -28.11
SD 0.68 4.94 0.24 5.56 1.09 19.42 27.70 13.19 1.03 26.64 0.20 14.45
Min -1.90 -13.97 -0.72 -15.71 -2.30 -51.11 -68.00 -37.78 -1.63 -46.84 -0.75 -57.69
Max 0.20 1.43 -0.02 -0.43 1.60 23.53 13.00 7.00 2.06 49.76 -0.10 -6.94
Baseline values before cycle 1 were compared with lowest values during follow-up. Absolute and relative changes are presented. On average, a slight to 
moderate decrease was noted for all cell lines.
SD = Standard deviation; Min = Minimum; Max = Maximum.
Table 2: Ra-223 treatment summary
Patient 1 2 3 4 5 6 7 8 9 10
1st cycle Ra-223 Jun 2014 May 2014 Mar 2015 Jul 2014 Dec 2013 Aug 2014 Jul 2015 Jan 2014 Dec 2013 Nov 2015
No. of cycles 
(cumulative 
activity in 
MBq)
6
(21,90 MBq)
6
(22,12 MBq)
3
(10,41 MBq)
6
(18,64 
MBq)
6
(27,49 
MBq)
6
(30,67 MBq)
6
(30,54 MBq)
6
(21,13 MBq)
3
(18,96 MBq)
2 
(7,40 MBq)
Early 
discontinuation No No Yes No No No No No Yes Yes
Reason of 
discontinuation - -
Neutropenia, 
lymphopenia - - - - -
Liver 
metastasis
Progressive 
lymph node 
metastasis
Ra-223-related 
adverse events - -
Neutropenia, 
lymphopenia Fatigue - -
Fatigue, 
nausea, 
abdominal 
discomfort
- - -
ALP (U/l) at 1st
cycle Ra-223
173 52 159 63 360 92 108 79 73 85
PSA (ng/mL) 
at 1st cycle 
Ra-223
0.11 0.81 529 2.21 0.64 89 0.16 30 3.2 0.8
Concomitant 
medical 
treatment
Bicalutamide, 
LHRH-A
Bicalutamide, 
LHRH-A
Bicalutamide, 
LHRH-A LHRH-A LHRH-A
Bicalutamide, 
LHRH-A
Bicalutamide, 
LHRH-A
Bicalutamide, 
LHRH-A
Bicalutamide, 
LHRH-A LHRH-A
ALP response
(baseline → 
follow-up)
SD SD SD SD PR PR PR PR SD SD
Response on 
BS
(EOD baseline 
→ EOD 
follow-up)
PD
(1→2)
SD
(3→3)
SD
(3→3)
PR
(3→1)
PR
(3→2)
SD
(3→3)
SD
(1→1)
PR
(2→1)
- -
EOD grade classification (modified according to Takahashi et al., 2012 [19]): 0 - normal or abnormal findings due to benign bone disease; 1 - ≤6 bone metastases, (each of 
which is ≤50% of the size of the size of a vertebral body); 2 - between 6 and 20 bone metastases; 3 - >20 bone metastases but less than or equal to that on a ‘‘super bone scan’’; 
4 - ‘‘super bone scan’’ or its equivalent (eg, metastasis to >75% of the ribs, vertebrae, and pelvic bones).
Ra-223 = Radium-223 dichloride; MBq = Megabecquerel; PSA = Prostate-specific antigen; LHRH-A = Luteinizing hormone-releasing hormone agonist; ALP = Alkaline 
phosphatase; BS = Bone scintigraphy; EOD = Extent of disease; SD = Stable disease; PR = Partial remission; PD = Progressive disease.
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Figure 1: (a-c) Changes in ALP (a), PSA (b), and pain intensity (c) during Ra-223 therapy. The changes in ALP and PSA values are 
presented during therapy (before cycle 4), at the end of Ra-223 therapy (before cycle 6) and during follow-up (up to 8 weeks after cycle 6) 
compared to baseline values before cycle 1. The mean pain intensity decreased by 43 ± 44% during therapy (before cycle 4) and by 45 ± 
41% at the end of treatment compared to baseline values before cycle 1.
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Ra-223 therapy was associated with pain relief 
in our patient cohort. This finding is in line with 
results from the ALSYMPCA trial, in which patients 
reported pain reduction following Ra-223 treatment 
[9]. According to EOD classification [19, 20], Ra-223 
treatment showed partial remission in three of eight 
patients, and stable disease in four of eight patients on 
bone scintigraphy. However, the clinical value of bone 
scintigraphy response to Ra-223 treatment has not been 
validated so far.
These promising findings did not result in a 
general change of treatment decisions at our academic 
center. Generally, our approach in M1 PCa patients with 
symptomatic bone metastases and lymph node disease at 
time of diagnosis is still chemohormonal therapy, stratified 
by high- or low-volume disease. However, selected men 
are now offered RP with cytoreductive intent followed by 
Ra-223 treatment if chemotherapy is contraindicated as 
experimental approach.
Limitations to our study include the heterogeneous 
patient population, the small cohort size and the 
retrospective design. Reimbursement for the off-
label Ra-223 treatment was provided by the patient’s 
health insurance after individual application, creating 
a possible selection bias. The effect of ADT in 
combination with RP and Ra-223 is unclear; however, 
considering the mechanism of action of both ADT and 
Ra-223 a synergistic effect can be postulated. Given the 
short follow-up, no information on survival could be 
obtained.
Despite these limitations, this study represents the 
first case series investigating off-label use of Ra-223 
for primary bone metastases in patients with mHSPC 
after RP and therefore may influence the design of future 
randomized trials. The concomitant use of Ra-223 with 
abiraterone or enzalutamide in patients with mHSPC 
may also be possible - a treatment combination that has 
already been shown to be safe in mCRPC patients with 
bone metastases [21].
Our results suggest that off-label use of Ra-223 
for primary bone metastases in patients with hormone-
sensitive PCa after RP is feasible and alleviates pain. 
In addition, these results confirm that ALP, rather than 
PSA, seems to be a good marker for treatment response. 
Therefore, Ra-223 may be taken into consideration 
as part of multimodal treatment for advanced PCa in 
carefully selected patients.
Figure 2: (a-c) Significant disease regression on bone scintigraphy (BS) after completion of Ra-223 treatment (patient 5). (a) (left): BS 
before start of therapy (before cycle 1): Evidence of disseminated bone metastasis of vertebrae, rips, pelvis and femora. (b) (center): BS 
during therapy (between cycles 3 and 4): No significant change from baseline. (c) (right): BS at follow-up visit: Significant decrease of 
tracer uptake in disseminated bone metastasis of the vertebrae, rips, pelvis and the femora compared to baseline BS. No evidence of new 
bone lesions.
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Figure 3: (a-c) Fused Single Photon Emission Computed Tomography (SPECT)/CT images clearly depicting a decreasing radionuclide 
uptake in the bone metastases (patient 4). (a) (top row): SPECT/CT before start of therapy (before cycle 1): Evidence of disseminated bone 
metastasis with high radionuclide uptake. (b) (middle row): SPECT/CT during therapy (between cycles 3 and 4): Decreasing uptake in bone 
metastases. (c) (bottom row): SPECT/CT at follow-up visit: Significantly decreasing and missing radionuclide uptake in bone metastases 
compared to baseline images. No evidence of new bone lesions.
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MATERIALS AND METHODS
Patient population and surgical procedure
Ten patients with histologically confirmed, 
hormone-sensitive prostate cancer (HSPC) and 
radiological or scintigraphic evidence of ≥2 bone 
metastases were assessed. Patients underwent RP at the 
Department of Urology, Ludwig-Maximilians-University, 
Munich between September 2012 and March 2015. RP 
was performed with cytoreductive intent on the basis of an 
experimental oncologic rationale as described previously 
[12, 13]. Bilateral pLND was performed simultaneously. 
ADT was initiated after RP and before Ra-223 treatment, 
and was given continuously. ADT included luteinizing 
hormone-releasing hormone agonist ± bicalutamide (Table 
2). The study was approved by the local ethics committee 
(UE-Nr-158-16).
Study design and Ra-223 treatment
In this pilot feasibility study, the following 
inclusion and exclusion criteria needed to be met: Prior 
to the first cycle of Ra-223, BS and CT of the abdomen 
and thorax were performed to confirm bone involvement 
and to exclude visceral metastases. Only patients without 
lymph nodes >3 cm in short-axis diameter and visceral 
metastases on CT were included. Patients after systemic 
chemotherapy, radionuclide therapy or external beam 
radiotherapy were excluded. Ra-223 treatment was 
initiated if hemoglobin level was >10 g/dL, absolute 
neutrophil count ≥1.5 g/L, and thrombocytes ≥100 g/L. 
Ra-223 (Xofigo®) was acquired from Bayer Healthcare 
AG (Leverkusen, Germany). Patients were administered 
intravenous Ra-223 at 50 kBq/kg body weight every 4 
weeks (cumulative activities per patient are listed in Table 
2). The follow-up visit was scheduled 6-8 weeks after 
the last administration of Ra-223. At each visit, absolute 
blood count (hemoglobin, erythrocytes, leukocytes, 
thrombocytes, neutrophils and lymphocytes) was 
evaluated to assess bone marrow function and classified 
using the Common Terminology Criteria for Adverse 
Events (CTCAE; version 4.0 [22]). Treatment was 
continued as long as absolute blood count was ≥1.0 g/L 
for neutrophils and ≥50 g/L for thrombocytes. Otherwise, 
the decision to discontinue Ra-223 in a patient was based 
on the treating physicians’ discretion and included newly 
diagnosed visceral metastases during Ra-223 treatment. 
ALP and PSA were acquired prior cycle 1, 4, 6 and at 
follow-up or discontinuation visit. Written informed 
consent was obtained from each participant before start of 
Ra-223 treatment.
Clinical assessment
Mean bone pain intensity, using the four items 
measuring pain intensity (worst and least pain in the 
last 24 hours, average pain and pain right now) from the 
self-reporting Brief Pain Inventory (BPI) questionnaire 
was recorded before, during and at the end of therapy 
[15]. Patients were asked to report on bone pain only. 
Treatment-related adverse events were assessed at each 
visit.
Bone scintigraphy
BS was performed at baseline, 1 month after three 
and 6-8 weeks after completion of all six cycles. In 
brief, 632 ± 22.5 MBq 99mTc-phosphonates (TECEOS, 
CIS bio GmbH, Berlin, Germany) were injected 
intravenously. Whole-body scans were performed using 
a dedicated gamma camera (Siemens Symbia Intevo 
16/6/2; 2014; Siemens Healthcare, Erlangen, Germany). 
Routine anterior and posterior whole-body images 
were obtained 3–4 h after injection (256×1024 matrix; 
scanning speed 15 cm/min). Single Photon Emission 
Computed Tomography (SPECT)/CT imaging of the 
thorax, abdomen and pelvis was performed subsequently 
to better characterize the presence, location and extent of 
disease (180° circular orbit, 64 steps, 128×128 matrix, 
and 20s/step). CT was performed as low-dose CT for 
attenuation correction (130 kV, 20mAS, pitch 1.5, CT 
slices 5 mm). A dedicated software package was used 
for image reading (Hermes Hybrid Viewer, version 2.0; 
Hermes Medical Solutions, Stockholm, Sweden). Images 
were interpreted by consensus of two experienced nuclear 
medicine physicians, who were blinded to PSA and ALP 
levels, and pain scores. BS was scored according to EOD 
classification [19].
Statistical analysis
Changes (mean ± standard deviation) in PSA, ALP, 
and BPI score, as well as absolute and relative changes in 
blood count from baseline were assessed. Additionally, we 
classified ALP and PSA response to Ra-223 treatment in 
each patient.
Abbreviations
ADT: androgen deprivation therapy; ALP: 
alkaline phosphatase; BPI: Brief Pain Inventory; BS: 
bone scintigraphy; CT: computed tomography; EOD: 
extent of disease; MBq: Megabecquerel; mCRPC: 
metastatic castration-resistant prostate cancer; mHSPC: 
metastatic hormone-sensitive prostate cancer; PCa: 
prostate cancer; PET: positron emission tomography; 
pLND: pelvic lymph node dissection; QOL: quality of 
life; PSA: prostate-specific antigen; Ra-223: radium-223 
dichloride; RP: radical prostatectomy; SPECT: single 
photon emission computed tomography; SRE: skeletal-
related event.
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